{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T14:14:36Z","timestamp":1783692876582,"version":"3.55.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guizhou Province Graduate Student Research Fund Project","award":["QiankeheYJSKYJJ[2021]171"],"award-info":[{"award-number":["QiankeheYJSKYJJ[2021]171"]}]},{"name":"Guizhou Province Graduate Student Research Fund Project","award":["QiankeheYJSKYJJ[2021]171"],"award-info":[{"award-number":["QiankeheYJSKYJJ[2021]171"]}]},{"name":"Shaoxing Science and Technology Planning Project","award":["2023A14013"],"award-info":[{"award-number":["2023A14013"]}]},{"name":"The State Administration of Traditional Chinese Medicine high-level key discipline construction project","award":["zyyzdxk-2023185"],"award-info":[{"award-number":["zyyzdxk-2023185"]}]},{"name":"Guizhou Key Laboratory of Modern Traditional Chinese Medicine Creation","award":["Qian Ke He Platform ZSYS [2025] 019"],"award-info":[{"award-number":["Qian Ke He Platform ZSYS [2025] 019"]}]},{"name":"High-level Innovative Talents of Guizhou Province","award":["QianKeHe platform talents-GCC [2023] 047"],"award-info":[{"award-number":["QianKeHe platform talents-GCC [2023] 047"]}]},{"name":"Guizhou Province Innovation Talent Team Construction","award":["Platform Talent-CXTD[2023]020"],"award-info":[{"award-number":["Platform Talent-CXTD[2023]020"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82360852"],"award-info":[{"award-number":["82360852"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Nano-drug Technology Research Center of Guizhou University of Traditional Chinese Medicine","award":["Guizhongyi ZX Hezi [2024] 070"],"award-info":[{"award-number":["Guizhongyi ZX Hezi [2024] 070"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-36920-5","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T19:36:02Z","timestamp":1769196962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CKAAKN peptide-conjugated long-circulating nanoliposomes for the targeted delivery of oridonin to pancreatic cancers"],"prefix":"10.1038","volume":"16","author":[{"given":"Fangxia","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunshun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyan","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"issue":"5","key":"36920_CR1","doi-asserted-by":"publisher","first-page":"681","DOI":"10.4149\/neo_2018_181020N786","volume":"66","author":"D Tang","year":"2019","unstructured":"Tang, D. et al. Identification of key pathways and genes changes in pancreatic cancer cells (BXPC-3) after cross-talk with primary pancreatic stellate cells using bioinformatics analysis. Neoplasma 66(5), 681\u2013693 (2019).","journal-title":"Neoplasma"},{"issue":"23","key":"36920_CR2","doi-asserted-by":"publisher","first-page":"16814","DOI":"10.3390\/ijms242316814","volume":"24","author":"M Gyoten","year":"2023","unstructured":"Gyoten, M. et al. Lovastatin treatment inducing apoptosis in human pancreatic cancer cells by inhibiting cholesterol rafts in plasma membrane and mitochondria. Int J Mol Sci. 24(23), 16814 (2023).","journal-title":"Int J Mol Sci."},{"issue":"4","key":"36920_CR3","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/ajco.14166","volume":"21","author":"A Nerwal","year":"2025","unstructured":"Nerwal, A. et al. Neoadjuvant chemotherapy with chemoradiotherapy for patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma-retrospective review from a tertiary care hospital. Asia Pac. J. Clin. Oncol. 21(4), 392\u2013398 (2025).","journal-title":"Asia Pac. J. Clin. Oncol."},{"issue":"1","key":"36920_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41392-022-01304-4","volume":"8","author":"L Yang","year":"2023","unstructured":"Yang, L. et al. Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy. Signal. Transduct Target Ther. 8(1), 35 (2023).","journal-title":"Signal. Transduct Target Ther."},{"issue":"16","key":"36920_CR5","doi-asserted-by":"publisher","first-page":"e191939","DOI":"10.1172\/JCI191939","volume":"135","author":"K Drizyte-Miller","year":"2025","unstructured":"Drizyte-Miller, K. et al. KRAS: the Achilles\u2019 heel of pancreas cancer biology. J. Clin. Invest. 135(16), e191939 (2025).","journal-title":"J. Clin. Invest."},{"issue":"6","key":"36920_CR6","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1007\/s00534-013-0616-0","volume":"20","author":"S Satoi","year":"2013","unstructured":"Satoi, S. et al. Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J. Hepatobiliary Pancreat Sci. 20(6), 590\u2013600 (2013).","journal-title":"J. Hepatobiliary Pancreat Sci."},{"issue":"1","key":"36920_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1001\/jamaoncol.2019.3394","volume":"6","author":"GS Jameson","year":"2020","unstructured":"Jameson, G. S. et al. Response rate following albumin-bound paclitaxel plus gemcitabine plus cisplatin treatment among patients with advanced pancreatic cancer: a phase 1b\/2 pilot clinical trial. JAMA Oncol. 6(1), 125\u2013132 (2020).","journal-title":"JAMA Oncol."},{"issue":"16","key":"36920_CR8","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1038\/onc.2015.270","volume":"35","author":"S Calabretta","year":"2016","unstructured":"Calabretta, S. et al. Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells. Oncogene 35(16), 2031\u20132039 (2016).","journal-title":"Oncogene"},{"key":"36920_CR9","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jconrel.2021.07.020","volume":"337","author":"RJ Browning","year":"2021","unstructured":"Browning, R. J. et al. Combining sonodynamic therapy with chemoradiation for the treatment of pancreatic cancer. J. Control Release. 337, 371\u2013377 (2021).","journal-title":"J. Control Release."},{"issue":"11","key":"36920_CR10","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1039\/D4TB02206H","volume":"13","author":"G Zhou","year":"2025","unstructured":"Zhou, G. et al. A biomimetic dual-targeting nanomedicine for pancreatic cancer therapy. J. Mater. Chem. B. 13(11), 3716\u20133729 (2025).","journal-title":"J. Mater. Chem. B."},{"key":"36920_CR11","first-page":"645824","volume":"12","author":"X Li","year":"2021","unstructured":"Li, X. et al. Oridonin: a review of its pharmacology. Pharmacokinetics and Toxicity. Front Pharmacol. 12, 645824 (2021).","journal-title":"Pharmacokinetics and Toxicity. Front Pharmacol."},{"issue":"1","key":"36920_CR12","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1186\/s12935-024-03533-9","volume":"24","author":"R Liu","year":"2024","unstructured":"Liu, R. et al. Erianin inhibits the progression of pancreatic cancer by directly targeting AKT and ASK1. Cancer Cell Int. 24(1), 348 (2024).","journal-title":"Cancer Cell Int."},{"issue":"4","key":"36920_CR13","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.62347\/CGIO2604","volume":"15","author":"B Shao","year":"2025","unstructured":"Shao, B. et al. Autophagy-dependent apoptosis induction by oridonin are mediated by ROS-dependent AMPK-mTOR-ULK1 pathway in colon cancer. Am. J. Cancer Res. 15(4), 1902\u20131918 (2025).","journal-title":"Am. J. Cancer Res."},{"key":"36920_CR14","first-page":"1793","volume":"7","author":"X Qi","year":"2012","unstructured":"Qi, X. et al. Oridonin nanosuspension was more effective than free oridonin on G2\/M cell cycle arrest and apoptosis in the human pancreatic cancer PANC-1 cell line. Int. J. Nanomedicine. 7, 1793\u20131804 (2012).","journal-title":"Int. J. Nanomedicine."},{"issue":"13","key":"36920_CR15","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.21037\/atm-21-2630","volume":"9","author":"X Zhao","year":"2021","unstructured":"Zhao, X. et al. Oridonin induces autophagy-mediated cell death in pancreatic cancer by activating the c-Jun N-terminal kinase pathway and inhibiting phosphoinositide 3-kinase signaling. Ann. Trans. Med. 9(13), 1084 (2021).","journal-title":"Ann. Trans. Med."},{"key":"36920_CR16","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jconrel.2024.11.032","volume":"377","author":"P Li","year":"2025","unstructured":"Li, P. et al. Hypoxia-responsive liposome enhances intracellular delivery of photosensitizer for effective photodynamic therapy. J. Control. Release. 377, 277\u2013287 (2025).","journal-title":"J. Control. Release."},{"issue":"8","key":"36920_CR17","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1007\/s13346-024-01770-z","volume":"15","author":"G Sharma","year":"2025","unstructured":"Sharma, G. et al. Revolutionizing Parkinson\u2019s treatment: Harnessing the potential of intranasal nanoemulsions for targeted therapy. Drug. Deliv. Trans. Res. 15(8), 2589\u20132607 (2025).","journal-title":"Drug. Deliv. Trans. Res."},{"key":"36920_CR18","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.2147\/IJN.S450853","volume":"19","author":"SH Lim","year":"2024","unstructured":"Lim, S. H. et al. Nanoparticle-based combinational strategies for overcoming the blood-brain barrier and blood-Tumor barrier. Int. J. Nanomedicine. 19, 2529\u20132552 (2024).","journal-title":"Int. J. Nanomedicine."},{"key":"36920_CR19","doi-asserted-by":"publisher","first-page":"rbae126","DOI":"10.1093\/rb\/rbae126","volume":"11","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. Nanomaterials based on hollow gold nanospheres for cancer therapy. Regen Biomater. 11, rbae126 (2024).","journal-title":"Regen Biomater."},{"issue":"13","key":"36920_CR20","doi-asserted-by":"publisher","first-page":"4166","DOI":"10.1039\/D4TB02789B","volume":"13","author":"T Shah","year":"2025","unstructured":"Shah, T. et al. Computational design to experimental validation: molecular dynamics-assisted development of polycaprolactone micelles for drug delivery. J. Mater. Chem. B. 13(13), 4166\u20134178 (2025).","journal-title":"J. Mater. Chem. B."},{"key":"36920_CR21","doi-asserted-by":"publisher","first-page":"142832","DOI":"10.1016\/j.ijbiomac.2025.142832","volume":"313","author":"MT El-Saadony","year":"2025","unstructured":"El-Saadony, M. T. et al. Chitosan, derivatives, and its nanoparticles: Preparation, physicochemical properties, biological activities, and biomedical applications\u2014a comprehensive review. Int. J. Biol. Macromol. 313, 142832 (2025).","journal-title":"Int. J. Biol. Macromol."},{"issue":"2","key":"36920_CR22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3390\/cells14020061","volume":"14","author":"E Pashkina","year":"2025","unstructured":"Pashkina, E. et al. Hyaluronic acid-based drug delivery systems for cancer therapy. Cells 14(2), 61 (2025).","journal-title":"Cells"},{"key":"36920_CR23","doi-asserted-by":"publisher","first-page":"113562","DOI":"10.1016\/j.jconrel.2025.02.058","volume":"381","author":"L Liu","year":"2025","unstructured":"Liu, L. et al. Nanobody-based drug delivery systems for cancer therapy. J. Control. Release. 381, 113562 (2025).","journal-title":"J. Control. Release."},{"issue":"5","key":"36920_CR24","doi-asserted-by":"publisher","first-page":"e2100639","DOI":"10.1002\/adhm.202100639","volume":"11","author":"L van der Koog","year":"2022","unstructured":"van der Koog, L. et al. Liposomes and extracellular vesicles as drug delivery systems: a comparison of composition, pharmacokinetics, and functionalization. Adv. Healthc Mater. 11(5), e2100639 (2022).","journal-title":"Adv. Healthc Mater."},{"key":"36920_CR25","doi-asserted-by":"publisher","first-page":"124994","DOI":"10.1016\/j.ijpharm.2024.124994","volume":"668","author":"HAC Odel","year":"2025","unstructured":"Odel, H. A. C. et al. Liposomes and niosomes: new trends and applications in the delivery of bioactive agents for cancer therapy. Int J Pharm. 668, 124994 (2025).","journal-title":"Int J Pharm."},{"issue":"6","key":"36920_CR26","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1021\/acsbiomaterials.5c00218","volume":"11","author":"B Yu","year":"2025","unstructured":"Yu, B. et al. Empowering healthcare with phage display technology. ACS Biomater. Sci. Eng. 11(6), 3228\u20133248 (2025).","journal-title":"ACS Biomater. Sci. Eng."},{"issue":"1","key":"36920_CR27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41392-025-02292-x","volume":"10","author":"C Zhou","year":"2025","unstructured":"Zhou, C. et al. Serine\/threonine\/tyrosine kinase 1 drives pancreatic carcinogenesis via GSK3\u03b2 sequestration-mediated Wnt\/\u03b2-catenin pathway hyperactivation. Signal Transduct Target Ther. 10(1), 205 (2025).","journal-title":"Signal Transduct Target Ther."},{"issue":"1","key":"36920_CR28","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41392-022-01268-5","volume":"8","author":"C Zhou","year":"2023","unstructured":"Zhou, C. et al. B-lymphoid tyrosine kinase-mediated FAM83A phosphorylation elevates pancreatic tumorigenesis through interacting with \u03b2-catenin. Signal Transduct Target Ther. 8(1), 66 (2023).","journal-title":"Signal Transduct Target Ther."},{"key":"36920_CR29","doi-asserted-by":"publisher","first-page":"117892","DOI":"10.1016\/j.biopha.2025.117892","volume":"184","author":"CM Hu","year":"2025","unstructured":"Hu, C. M. et al. Innovative cyclic peptide disrupts IL-17RB-MLK4 interaction for targeted pancreatic cancer therapy. Biomed. Pharmacother. 184, 117892 (2025).","journal-title":"Biomed. Pharmacother."},{"issue":"12","key":"36920_CR30","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.3390\/ijms20122988","volume":"20","author":"X Zhu","year":"2019","unstructured":"Zhu, X. et al. Targeting pancreatic cancer cells with peptide-functionalized polymeric magnetic nanoparticles. Int. J. Mol. Sci. 20(12), 2988 (2019).","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"36920_CR31","doi-asserted-by":"publisher","first-page":"686","DOI":"10.2174\/1381612829666230324091555","volume":"29","author":"L Lu","year":"2023","unstructured":"Lu, L. et al. Preparation and characterization of PLGA-based magnetic polymer nanoparticles for targeting pancreatic adenocarcinoma. Curr. Pharm. Des. 29(9), 686\u2013696 (2023).","journal-title":"Curr. Pharm. Des."},{"key":"36920_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jconrel.2014.06.039","volume":"192","author":"S Valetti","year":"2014","unstructured":"Valetti, S. et al. Peptide-functionalized nanoparticles for selective targeting of pancreatic tumor. J. Control. Release. 192, 29\u201339 (2014).","journal-title":"J. Control. Release."},{"issue":"11","key":"36920_CR33","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1021\/bc5003423","volume":"25","author":"S Valetti","year":"2014","unstructured":"Valetti, S. et al. Peptide conjugation: before or after nanoparticle formation?. Bioconjug Chem. 25(11), 1971\u20131983 (2014).","journal-title":"Bioconjug Chem."},{"issue":"9","key":"36920_CR34","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.5650\/jos.ess21033","volume":"70","author":"L Hou","year":"2021","unstructured":"Hou, L. et al. Effects of phytosterol butyrate ester on the characteristics of soybean phosphatidylcholine liposomes. J. Oleo Sci. 70(9), 1295\u20131306 (2021).","journal-title":"J. Oleo Sci."},{"issue":"1","key":"36920_CR35","first-page":"129","volume":"12","author":"C Hong","year":"2020","unstructured":"Hong, C. et al. One stone four birds: a novel liposomal delivery system multi-functionalized with ginsenoside Rh2 for tumor targeting therapy. Nanomicro Lett. 12(1), 129 (2020).","journal-title":"Nanomicro Lett."},{"issue":"2","key":"36920_CR36","doi-asserted-by":"publisher","first-page":"319","DOI":"10.7150\/thno.18078","volume":"7","author":"X Sun","year":"2017","unstructured":"Sun, X. et al. Improved tumor uptake by optimizing liposome based RES blockade strategy. Theranostics. 7(2), 319\u2013328 (2017).","journal-title":"Theranostics."},{"issue":"29","key":"36920_CR37","doi-asserted-by":"publisher","first-page":"10327","DOI":"10.1039\/C7NR03042H","volume":"9","author":"M Papi","year":"2017","unstructured":"Papi, M. et al. Clinically approved PEGylated nanoparticles are covered by a protein corona that boosts the uptake by cancer cells. Nanoscale 9(29), 10327\u201310334 (2017).","journal-title":"Nanoscale"},{"issue":"3","key":"36920_CR38","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.1021\/acsnano.6b00261","volume":"10","author":"A Bigdeli","year":"2016","unstructured":"Bigdeli, A. et al. Exploring cellular interactions of liposomes using protein corona fingerprints and physicochemical properties. ACS Nano 10(3), 3723\u20133737 (2016).","journal-title":"ACS Nano"},{"key":"36920_CR39","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.2147\/IJN.S109059","volume":"11","author":"C Corbo","year":"2016","unstructured":"Corbo, C. et al. Effects of the protein corona on liposome-liposome and liposome-cell interactions. Int. J. Nanomedicine. 11, 3049\u20133063 (2016).","journal-title":"Int. J. Nanomedicine."},{"issue":"27","key":"36920_CR40","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.3748\/wjg.v28.i27.3297","volume":"28","author":"C Smith","year":"2022","unstructured":"Smith, C. et al. Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy. World J. Gastroenterol. 28(27), 3297\u20133313 (2022).","journal-title":"World J. Gastroenterol."},{"issue":"11","key":"36920_CR41","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1016\/j.apsb.2023.05.018","volume":"13","author":"Q Liu","year":"2023","unstructured":"Liu, Q. et al. Current research trends of nanomedicines. Acta Pharm. Sin B. 13(11), 4391\u20134416 (2023).","journal-title":"Acta Pharm. Sin B."},{"key":"36920_CR42","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.addr.2020.06.005","volume":"157","author":"J Fang","year":"2020","unstructured":"Fang, J. et al. Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers. Adv. Drug. Deliv Rev. 157, 142\u2013160 (2020).","journal-title":"Adv. Drug. Deliv Rev."},{"issue":"6","key":"36920_CR43","doi-asserted-by":"publisher","first-page":"e1285","DOI":"10.1002\/ctm2.1285","volume":"13","author":"N Krishnan","year":"2023","unstructured":"Krishnan, N. et al. Cell membrane-coated nanoparticles for the treatment of cancer. Clin Transl. Med. 13(6), e1285 (2023).","journal-title":"Clin Transl. Med."},{"issue":"1","key":"36920_CR44","doi-asserted-by":"publisher","first-page":"44","DOI":"10.2174\/1566524018666180416101522","volume":"18","author":"A Jain","year":"2018","unstructured":"Jain, A. et al. Advances in tumor targeted liposomes. Curr. Mol. Med. 18(1), 44\u201357 (2018).","journal-title":"Curr. Mol. Med."},{"issue":"3","key":"36920_CR45","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.3390\/ijms24032643","volume":"24","author":"S Wang","year":"2023","unstructured":"Wang, S. et al. Liposomes for tumor targeted therapy: a review. Int. J. Mol. Sci. 24(3), 2643 (2023).","journal-title":"Int. J. Mol. Sci."},{"issue":"17","key":"36920_CR46","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.4155\/fmc-2016-0135","volume":"8","author":"S Fathi","year":"2016","unstructured":"Fathi, S. et al. Liposomal drug delivery systems for targeted cancer therapy: is active targeting the best choice?. Future Med. Chem. 8(17), 2091\u20132112 (2016).","journal-title":"Future Med. Chem."},{"key":"36920_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2018.02.040","volume":"277","author":"L Belfiore","year":"2018","unstructured":"Belfiore, L. et al. Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities. J. Control. Release. 277, 1\u201313 (2018).","journal-title":"J. Control. Release."},{"issue":"12","key":"36920_CR48","doi-asserted-by":"publisher","first-page":"857","DOI":"10.4155\/tde-2018-0035","volume":"9","author":"S Deodhar","year":"2018","unstructured":"Deodhar, S. et al. Long circulating liposomes: challenges and opportunities. Ther. Deliv. 9(12), 857\u2013872 (2018).","journal-title":"Ther. Deliv."},{"issue":"10","key":"36920_CR49","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1080\/10837450.2021.1982966","volume":"26","author":"C Gao","year":"2021","unstructured":"Gao, C. et al. Preparation, characterization, and anti-colon cancer activity of oridonin-loaded long-circulating liposomes. Pharm. Dev. Technol. 26(10), 1073\u20131078 (2021).","journal-title":"Pharm. Dev. Technol."},{"issue":"7","key":"36920_CR50","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/0165-6147(94)90314-X","volume":"15","author":"TM Allen","year":"1994","unstructured":"Allen, T. M. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci. 15(7), 215\u2013220 (1994).","journal-title":"Trends Pharmacol Sci."},{"issue":"10","key":"36920_CR51","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/nnano.2013.181","volume":"8","author":"S Tenzer","year":"2013","unstructured":"Tenzer, S. et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat. Nanotechnol. 8(10), 772\u2013781 (2013).","journal-title":"Nat. Nanotechnol."},{"issue":"21","key":"36920_CR52","doi-asserted-by":"publisher","first-page":"6485","DOI":"10.1021\/la401192x","volume":"29","author":"AL Barr\u00e1n-Berd\u00f3n","year":"2013","unstructured":"Barr\u00e1n-Berd\u00f3n, A. L. et al. Time evolution of nanoparticle-protein corona in human plasma: relevance for targeted drug delivery. Langmuir 29(21), 6485\u20136494 (2013).","journal-title":"Langmuir"},{"issue":"8","key":"36920_CR53","doi-asserted-by":"publisher","first-page":"6555","DOI":"10.1021\/nn305337c","volume":"7","author":"M Mahmoudi","year":"2013","unstructured":"Mahmoudi, M. et al. Temperature: the \u201cignored\u201d factor at the NanoBio interface. ACS Nano 7(8), 6555\u20136562 (2013).","journal-title":"ACS Nano"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36920-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36920-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36920-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:02:41Z","timestamp":1770894161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36920-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["36920"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-36920-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All experimental procedures presented in this manuscript were approved and carried out in accordance with the China Veterinary Animal Care Office Animal Experimental Ethics Committee of Guizhou University of Traditional Chinese Medicine (Grant No.20230022). This study was reported in accordance with ARRIVE guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}}],"article-number":"6065"}}